Effect of Irradiation on Tissue Penetration Depth of Doxorubicin after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a Novel Ex-Vivo Model.
BACKGROUND
This study was performed to assess the impact of irradiation on the tissue penetration depth of doxorubicin delivered during Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC).


METHODS
Fresh post mortem swine peritoneum was cut into 10 proportional sections. Except for 2 control samples, all received irradiation with 1, 2, 7 and 14 Gy, respectively. Four samples received PIPAC 15 minutes after irradiation and 4 other after 24 hours. Doxorubicin was aerosolized in an ex-vivo PIPAC model at 12 mmHg/36°C. In-tissue doxorubicin penetration was measured using fluorescence microscopy on frozen thin sections.


RESULTS
Doxorubicin penetration after PIPAC (15 minutes after irradiation) was 476 ± 74 µm for the control sample, 450 ± 45µm after 1 Gy (p > 0.05), 438 ± 29 µm after 2 Gy (p > 0.05), 396 ± 32 µm after 7 Gy (p = 0.005) and 284 ± 57 after 14 Gy irradiation (p < 0.001). The doxorubicin penetration after PIPAC (24 hours after irradiation) was 428 ± 77 µm for the control sample, 393 ± 41 µm after 1 Gy (p > 0.05), 379 ± 56 µm after 2 Gy (p > 0.05), 352 ± 53 µm after 7 Gy (p = 0.008) and 345 ± 53 after 14 Gy irradiation (p = 0.001).


CONCLUSIONS
Higher (fractional) radiation dose might reduce the tissue penetration depth of doxorubicin in our ex-vivo model. However, irradiation with lower (fractional) radiation dose does not affect the tissue penetration negatively. Further studies are warranted to investigate if irradiation can be used safely as chemopotenting agent for patients with peritoneal metastases treated with PIPAC.
1. Department of General Surgery & Therapy Center for Peritonealcarcinomatosis, Marien Hospital Herne, Ruhr University Bochum, Germany.; 2. Basic Research Laboratory, Department of Surgery, Marien Hospital Herne, Ruhr University Bochum, Germany.
Veria
V
Khosrawipour
1. Department of General Surgery & Therapy Center for Peritonealcarcinomatosis, Marien Hospital Herne, Ruhr University Bochum, Germany.; 2. Basic Research Laboratory, Department of Surgery, Marien Hospital Herne, Ruhr University Bochum, Germany.
Urs
U
Giger-Pabst
2. Basic Research Laboratory, Department of Surgery, Marien Hospital Herne, Ruhr University Bochum, Germany.
Tanja
T
Khosrawipour
3. Department of Radiation Oncology, Marien Hospital Herne, Ruhr University Bochum, Germany.
Yousef Hedayat
YH
Pour
4. Department of Hematology & Medical Oncology, Marien Hospital Herne, Ruhr University Bochum, Germany.
David
D
Diaz-Carballo
5. Department of Neuroanatomy and Molecular Brain Research, Ruhr University Bochum, Germany.
Eckart
E
Förster
3. Department of Radiation Oncology, Marien Hospital Herne, Ruhr University Bochum, Germany.
Hugo
H
Böse-Ribeiro
3. Department of Radiation Oncology, Marien Hospital Herne, Ruhr University Bochum, Germany.
Irenäus Anton
IA
Adamietz
1. Department of General Surgery & Therapy Center for Peritonealcarcinomatosis, Marien Hospital Herne, Ruhr University Bochum, Germany.
Jürgen
J
Zieren
3. Department of Radiation Oncology, Marien Hospital Herne, Ruhr University Bochum, Germany.
Khashayar
K
Fakhrian
Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC); ex-vivo; penetration; peritoneal carcinomatosis; radiotherapy.